SARS-CoV-2 Mpro-IN-43

SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus main protease (Mpro) inhibitor (IC50: 72 μM) . SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research[1].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV; Virus Protease

Related Pathways

Anti-infection

Field of Research

Infection; Inflammation/Immunology

Smiles

S=C(N1CCN(CC2=CC(F)=C(F)C=C2F)CC1)S[C@H](C3=CCOC3=O)C[C@@H]4C(CC[C@]5([H])[C@](C)(CO)[C@H](O)CC[C@@]45C)=C

Molecular Formula

C32H41F3N2O4S2

Molecular Weight

638.80

References & Citations

[1]Suriya U, et al. Design and Evaluation of Andrographolide Analogues as SARS-CoV-2 Main Protease Inhibitors: Molecular Modeling and in vitro Studies. Drug Des Devel Ther. 2025 May 15;19:3907-3924.